Immunodiagnostic Systems Share Discussion Threads

[dasv] 26/11/2009 15:31

thanks for heads-up silverfern

[jm barrie100] 26/11/2009 13:39

silverfern - great post, thanks.

[silverfern] 26/11/2009 12:43

Here's one for you all : IBL - read today's RNS and you'll undertsand why Ive posted here. I'm not invested.

[dasv] 18/11/2009 11:24

new non-exec perhaps shares have been bought on his behalf?

[chester] 18/11/2009 08:32

Setting off for new Highs I feel.

[dasv] 20/10/2009 11:16

Seemingly inexorable.

[dil] 16/10/2009 16:42

Rarely trade shares these days Count prefer currencies now so get my fix from that. These are in the SIPP along with a few others and although I do use a stop it's a pretty wide one so not easily shaken out.

Sheep send their regards too Count and say they've missed you :-)

[dil] 16/10/2009 14:51

Charts looking better again today Count , sod the fundamentals :-)

Best regards

[the count] 16/10/2009 14:16

--->DIL

....over the years maybe.

Just because something is going up on a chart does not mean it cannot pause for fundamental valuation catchup first, perhaps for another 6 months consolidation maybe.

This should break through £10 in the next 2 - 3 years on a fairly conservative basis....hopefully sooner if sales speed up beyond analyst expectations.

Those lucky few that participated in the recent placing @ 130p must be feeling pretty pleased with their daylight robbery. The lowest I participated in there was to buy stock at 135p, which was close enough I guess.

Regards,

THE COUNT!

[dasv] 16/10/2009 13:26

EDD looks good too :)

[dil] 16/10/2009 00:34

Cracking chart lot more to come imo.

[dasv] 15/10/2009 13:01

another new high...

[alftupper] 08/10/2009 09:59

There remains a significant discount to its quoted peer Axis-Shield plus others - is this discount justifiable ?

[dasv] 06/10/2009 10:39

Diagnostics testing kit firm Immunodiagnostic Systems (IDH) reported an impressive 56% increase in revenues to 16.9 million pounds for the six months to September 30th. Sales of its Vitamin D tests have doubled, but lower sales of its automated instrument, IDS iSYS, are being offset by higher revenue per machine. Separately the company has announced that it has extended the scope of its agreement with Technogenetics of Italy. Technogenetics has been developing automated tests of autoimmune and infectious diseases to be used on the IDS iSYS for sale in Italy. Today's agreement extends the scope to all European and the former Soviet Union countries. "This should improve the attractiveness of the IDS iSYS platform and the competitive position of the company in Europe," commented broker Panmure Gordon. The broker increased its revenue forecasts for 2010 by 11% to 33.4 million pounds, which takes its EPS estimate 12% higher from 23.6p to 26.3p. Panmure Gordon reiterated its 'buy' stance for the shares, which rallied by 60p to 467.5p on the back of today's announcement.

[greek islander] 06/10/2009 00:09

Yes a real hedge against a turnround in the market.
Very impressive growth figures and I like the solid look of the forecasts for future trading.
Should be a 25-30% per year growth for many years to come and if that is not good enough for you, then you shouldn't be investing.

[baronet 1] 05/10/2009 21:13

5.10.09 10:01:48

Brewin Dolphin Raises Immunodiagnostic Systems IDH.L

Price Target to 510P from 335P;

Rating BUY


JB

[the count] 05/10/2009 14:19

--->EDDIECHALONER

OK EC.

Hope you have a few biccies in the biccy tin as well. LOL.

Will be in touch soon.

Regards,

THE COUNT!

[eddiechaloner] 05/10/2009 14:04

thanks

yes that will do it

[the count] 05/10/2009 13:43

--->EDDIECHALONER

.

[eddiechaloner] 05/10/2009 13:12

Hello Count

Best

EC

[the count] 05/10/2009 12:01

--->ALL

A little gem of a company with solid growth for years to come and as defensive a stock (important in tough times as it may trade at a premium to the marker when the penny drops) as you can get at this level.

I expect an share price of £10+ within 2 years... or 3 years if I am being very conservative.

This may not sound great when compared to blue sky dream tomorrow stocks such as in the exploration sector, but on a risk/reward basis, you cannot get much better than that.

Oh, and today...

* Panmure Gordon has a buy for Immunodiagnostic Services, raising target to 470p from 420p.

I presume these idiots mean Immunodiagnostic Systems Holdings of course.

Regards,

THE COUNT!

[dasv] 05/10/2009 11:41

shares must be tightly held - more impressive rising in a lacklustre day for the FTSE100 on the back of an excellent trading update:-

Immunodiagnostic Systems Holdings plc


Trading update


Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading
producer of diagnostic testing kits for the clinical and research markets,
announces a trading update for the six month period to 30 September 2009, prior
to the release of its half-yearly report on Monday, 30 November 2009.


Turnover from continuing operations for the period is 56% ahead of the
comparative period for last year at GBP16.9 million (2008: GBP10.8 million) and
20% ahead of 2008 H2 on a like for like basis. Revenues have increased in all
direct sales territories with substantial growth in the USA, France and
Germany. Sales of our Vitamin D products continue to grow at an impressive rate,
having doubled compared to same period last year.


The company has made progress in both sales and placements of our automated
instrument the IDS-iSYS following its launch at the end of February this year.
We have also launched three automated products; 25 Hydroxy vitamin D at the end
of February, P1NP in July and HGH in September. We have direct reagent rental
accounts in the UK, France, Germany, Austria
and Switzerland and have made instrument sales in Australia, Canada, Finland,
Italy, Spain, France and Switzerland.


The roll out of the IDS-iSYS is in its formative stages, and although initial
machine sales are a little lower than anticipated, it is pleasing to report that
revenue per machine is ahead of expectations. We expect the rate of sales and
placements to increase in H2 following the increase in the number of iSYS
evaluation sites towards the end of H1, the new agreement with Technogenetics
(announced today on RNS Reach) under which we will supply OEM instruments and
reagents to them, and, subject to the timing of FDA approval later this year,
the planned US launch of the iSYS system.


Overall trading remains in line with management expectations and the Board
remains confident going forward that it can continue to execute its plans for
the current year.

[chester] 05/10/2009 11:20

Lovely job.

[silverfern] 05/10/2009 08:13

Added this moninng - this company has a cash printing press now.